Clinical trial · Observational
Cardiovascular Complications of Carfilzomib
Insuffisance Cardiaque Sous Carfilzomib: étude Prospective
NCT04407858CI-TRIAL-00045476ICAREunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cardiovascular toxicity of carfilzomib, a last generation proteasome inhibitor, is highly incident according to retrospective data. Prospective cohort study of patients initiated on carfilzomib.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Heart Failure | — | UNRESOLVED | — |
| Hypertension | — | UNRESOLVED | — |
| Myeloma | Multiple Myeloma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Incidence of cardio-vasculo-toxicity of carfilzomib
- timeFrame
- 6 months
- description
- Number of patients with cardio-toxicity (composite endpoint) in a cohort of patients referred to a cardio-oncology before initiation of carfilzomib.
Secondary outcomes (6)
- measure
- Systemic hypertension
- timeFrame
- 6 months
- description
- Number of patients with as systemic hypertension
- measure
- Heart Failure Reduced Ejection Fraction
- timeFrame
- 6 months
- description
- Number of patients with Heart Failure and Reduced Ejection Fraction
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Intention to treat by Carfilzomib Exclusion Criteria: * History of carfilzomib treatment
References
Publications (0)
Data not yet available
No reference posted for this study.